All Stories

  1. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
  2. Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?
  3. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
  4. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
  5. The use of ibrutinib before and after allogeneic stem cell transplantation
  6. Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?
  7. A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model
  8. A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach
  9. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma
  10. Chemotherapy and Cardiotoxicity in Hematologic Malignancies
  11. Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of G-CSF: a Longitudinal, Prospective, Observational, Single-Center, Cohort Study
  12. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
  13. Sorafenib for the treatment of multiple myeloma
  14. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma
  15. The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma
  16. High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry
  17. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents
  18. The role of tandem stem cell transplantation for multiple myeloma patients
  19. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantatio...
  20. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study
  21. Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy
  22. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients
  23. Breast cancer circulating biomarkers: advantages, drawbacks, and new insights
  24. Mobilization of Hematopoietic Stem Cells with Lenograstim in Healthy Donors: Efficacy and Safety Analysis According to Donor Age
  25. High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer
  26. Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity
  27. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs
  28. Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control
  29. Smoldering multiple myeloma: to treat or not to treat
  30. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
  31. Tolerability and Efficacy of Busulfan and Fludarabine As Allogeneic Pretransplant Conditioning Therapy in Acute Myeloid Leukemia: Comparison With Busulfan and Cyclophosphamide Regimen
  32. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well
  33. Plerixafor: what we still have to learn
  34. Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation
  35. High-dose chemotherapy for germ cell tumors: do we have a model?
  36. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study
  37. Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study
  38. Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients
  39. Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
  40. Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry
  41. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization
  42. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study
  43. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs
  44. An old drug with a new future: bendamustine in multiple myeloma
  45. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma
  46. Diagnostic approaches for identifying acute graft-versus-host disease: what comes next?
  47. Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
  48. Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma
  49. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma
  50. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
  51. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry
  52. Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program
  53. Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?
  54. Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art
  55. A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease
  56. Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?
  57. Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma
  58. Internal Iliac Artery Perforation following Bone Marrow Aspiration in a Patient with No Previously Identified Risk Factors: A Case Report and Review of the Literature
  59. Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease
  60. Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells
  61. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience
  62. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
  63. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients
  64. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients
  65. Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF)
  66. Different γ/δ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation
  67. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study
  68. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting
  69. Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization
  70. 'In vivo' time course of plasma myeloperoxidase levels after granulocyte colony-stimulating factor-induced stem cell mobilization
  71. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
  72. Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor
  73. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim
  74. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients
  75. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients
  76. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy
  77. HIGH-DOSE ETOPOSIDE ENABLES THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WHO FAILED CYCLOPHOSPHAMIDE-INDUCED MOBILIZATION